Abstract
Despite the efficacy of IL-12 in cancer experimental models, clinical trials with systemic recombinant IL-12 showed unacceptable toxicity related to endogenous IFNγ production. We report that systemic administration of a recombinant adenovirus encoding IL-12 (AdCMVmIL-12) has a dramatically different survival outcome in a number of mouse pure strains over a wide range of doses. For instance at 2.5 × 109 p.f.u., systemic AdCMVmIL-12 killed all C57BL/6 mice but spared all BALB/c mice. Much higher IFNγ concentrations in serum samples of C57BL/6 than in those from identically treated BALB/c were found. Causes for heterogeneous toxicity can be traced to differences among murine strains in the levels of gene transduction achieved in the liver, as assessed with adenovirus coding for reporter genes. In accordance, IL-12 serum concentrations are higher in susceptible mice. In addition, sera from C57BL/6 mice treated with AdCMVmIL-12 showed higher levels of IL-18, a well-known IFNγ inducer. Interestingly, lethal toxicity in C57BL/6 mice was abolished by administration of blocking anti-IFNγ mAbs and also by simultaneous depletion of T cells, NK cells, and macrophages. These observations together with the great dispersion of IFNγ produced by human PBMCs upon in vitro stimulation with IL-12, or infection with recombinant adenovirus encoding IL-12, suggest that patients might also show heterogeneous degrees of toxicity in response to IL-12 gene transfer.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Shurin MR, Esche C, Peron JM, Lotze MT . Antitumor activities of IL-12 and mechanisms of action Chem Immunol 1997 68: 153–174
Trinchieri G . Interleukin-12: a cytokine at the interface of inflammation and immunity Adv Immunol 1998 70: 83–243
Scott P, Trinchieri G . IL-12 as an adjuvant for cell-mediated immunity Semin Immunol 1997 9: 285–291
Sgadari C, Angiolillo AL, Tosato G . Inhibition of angiogenesis by interleukin-12 is mediated by the interferon-inducible protein 10 Blood 1996 87: 3877–3882
Coughlin CM et al. Tumor cell responses to IFNgamma affect tumorigenicity and response to IL-12 therapy and antiangiogenesis Immunity 1998 9: 25–34
Grohmann U et al. IL-12 acts directly on DC to promote nuclear localization of NK-kappaB and primes DC for IL-12 production Immunity 1998 9: 315–323
Munder M, Mallo M, Eichmann K, Modolell M . Murine macrophages secrete interferon gamma upon combined stimulation with interleukin (IL)-12 and IL-18: A novel pathway of autocrine macrophage activation J Exp Med 1998 187: 2103–2108
Ohteki T et al. Interleukin 12-dependent interferon gamma production by CD8alpha+ lymphoid dendritic cells J Exp Med 1999 189: 1981–1986
Diefenbach A et al. Requirement for type 2 NO synthase for IL-12 signaling in innate immunity (published erratum appears in Science 1999 June 11; 284 (5421): 1997) Science 1999 284: 951–955
Robertson MJ et al. Immunological effects of interleukin 12 administered by bolus intravenous injection to patients with cancer Clin Cancer Res 1999 5: 9–16
Caruso M et al. Adenovirus-mediated interleukin-12 gene therapy for metastatic colon carcinoma Proc Natl Acad Sci USA 1996 93: 11302–11306
Bramson JL et al. Direct intratumoral injection of an adenovirus expressing interleukin-12 induces regression and long-lasting immunity that is associated with highly localized expression of interleukin-12 Hum Gene Ther 1996 7: 1995–2002
Douin-Echinard V et al. Enhancement of anti-tumor immunity by injection of fibroblasts genetically engineered to produce IL-12 and to express CD70 Adv Exp Med Biol 1998 451: 353–357
Toda M, Rabkin SD, Kojima H, Martuza RL . Herpes simplex virus as an in situ cancer vaccine for the induction of specific anti-tumor immunity Hum Gene Ther 1999 10: 385–393
Leonard JP et al. Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production Blood 1997 90: 2541–2548
Marshall E . Cancer trial of interleukin-12 halted Science 1995 268: 1555
Sacco S et al. Protective effect of a single interleukin-12 (IL-12) predose against the toxicity of subsequent chronic IL-12 in mice: role of cytokines and glucocorticoids Blood 1997 90: 4473–4479
Ryffel B . Interleukin-12: role of interferon-gamma in IL-12 adverse effects (see comments) Clin Immunol Immunopathol 1997 83: 18–20
Car BD, Eng VM, Lipman JM, Anderson TD . The toxicology of interleukin-12: a review Toxicol Pathol 1999 27: 58–63
Car BD et al. Role of interferon-gamma in interleukin 12-induced pathology in mice (see comments) Am J Pathol 1995 147: 1693–1707
Okamura H et al. Regulation of interferon-gamma production by IL-12 and IL-18 Curr Opin Immunol 1998 10: 259–264
Osaki T et al. Potent antitumor effects mediated by local expression of the mature form of the interferon-gamma inducing factor, interleukin-18 (IL-18) Gene Therapy 1999 6: 808–815
Gately MK et al. The interleukin-12/interleukin-12 receptor system: role in normal and pathologic immune responses Annu Rev Immunol 1998 16: 495–521
Reiner SL, Locksley RM . The regulation of immunity to Leishmania major Annu Rev Immunol 1995 13: 151–177
Lasarte JJ et al. Different doses of adenoviral vector expressing IL-12 enhance or depress the immune response to a coadministered antigen: the role of nitric oxide J Immunol 1999 162: 5270–5277
Lieber A et al. The role of Kupffer cell activation and viral gene expression in early liver toxicity after infusion of recombinant adenovirus vectors J Virol 1997 71: 8798–8807
Nemerow GR, Stewart PL . Role of alpha(v) integrins in adenovirus cell entry and gene delivery Microbiol Mol Biol Rev 1999 63: 725–734
Rook AH et al. Interleukin-12 therapy of cutaneous T-cell lymphoma induces lesion regression and cytotoxic T-cell responses Blood 1999 94: 902–908
Kitching AR, Tipping PG, Holdsworth SR . IL-12 directs severe renal injury, crescent formation and TH1 responses in murine glomerulonephritis Eur J Immunol 1999 29: 1–10
Carson WE et al. A fatal cytokine-induced systemic inflammatory response reveals a critical role for NK cells J Immunol 1999 162: 4943–4951
Boehm U, Klamp T, Groot M, Howard JC . Cellular responses to interferon-gamma Annu Rev Immunol 1997 15: 749–795
Dinarello CA . Interleukin-18 Methods 1999 19: 121–132
Koblish HK et al. Immune suppression by recombinant interleukin (rIL)-12 involves interferon gamma induction of nitric oxide synthase 2 (iNOS) activity: inhibitors of NO generation reveal the extent of rIL-12 vaccine adjuvant effect J Exp Med 1998 188: 1603–1610
Mazzolini G et al. Adenoviral gene transfer of interleukin 12 into tumors synergizes with adoptive T cell therapy both at the induction and effector level Hum Gene Ther 2000 11: 113–125
Mazzolini G et al. Regression of colon cancer and induction of antitumor immunity by intratumoral injection of adenovirus expressing interleukin-12 Cancer Gene Ther 1999 6: 514–522
Qian C, Bilbao R, Bruna O, Prieto J . Induction of sensitivity to ganciclovir in human hepatocellular carcinoma cells by adenovirus-mediated gene transfer of herpes simplex virus thymidine kinase Hepatology 1995 22: 118–123
Qian C et al. Gene transfer and therapy with adenoviral vectors in rats with diethylnitrosamine-induced hepatocellular carcinoma Hum Gene Ther 1997 8: 349–358
Melero I et al. NK1.1 cells express 4-1BB (CDw137) costimulatory molecule and are required for tumor immunity elicited by anti-4-1BB monoclonal antibodies Cell Immunol 1998 190: 167–172
Acknowledgements
We thank our colleagues Dr Bustos, Dr Novo and Dr Lasarte for their suggestions and critical reading. Technical assistance by Izaskun Gabari, Celia Gomar and Elena Villanueva is also acknowledged. Financial support was from CICYT (SAF98–0146, SAF99–0039 and SAF99–0084) and generous grants from Fundación Ramón Areces and Inés Bemberg.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Mazzolini, G., Narvaiza, I., Pérez-Diez, A. et al. Genetic heterogeneity in the toxicity to systemic adenoviral gene transfer of interleukin-12. Gene Ther 8, 259–267 (2001). https://doi.org/10.1038/sj.gt.3301387
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.gt.3301387
Keywords
This article is cited by
-
Identification and characterization of human nucleus pulposus cell specific serotypes of adeno-associated virus for gene therapeutic approaches of intervertebral disc disorders
BMC Musculoskeletal Disorders (2015)
-
Immunotherapy for liver tumors: present status and future prospects
Journal of Biomedical Science (2009)
-
PET imaging of thymidine kinase gene expression in the liver of non-human primates following systemic delivery of an adenoviral vector
Gene Therapy (2009)
-
Technology Insight: gene therapy and its potential role in the treatment of medullary thyroid carcinoma
Nature Clinical Practice Endocrinology & Metabolism (2007)
-
IL-12p70 and IL-18 gene-modified dendritic cells loaded with tumor antigen-derived peptides or recombinant protein effectively stimulate specific Type-1 CD4+ T-cell responses from normal donors and melanoma patients in vitro
Cancer Gene Therapy (2006)